Equities analysts expect Crispr Therapeutics AG (NASDAQ:CRSP) to announce earnings of ($1.16) per share for the current quarter, according to Zacks. Four analysts have made estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.87) and the lowest estimate coming in at ($1.25). Crispr Therapeutics posted earnings of $2.40 per share in the same quarter last year, which suggests a negative year-over-year growth rate of 148.3%. The business is scheduled to report its next quarterly earnings report on Monday, October 26th.
On average, analysts expect that Crispr Therapeutics will report full year earnings of ($4.74) per share for the current financial year, with EPS estimates ranging from ($5.01) to ($4.14). For the next fiscal year, analysts expect that the firm will post earnings of ($4.94) per share, with EPS estimates ranging from ($6.13) to ($3.48). Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last released its earnings results on Monday, July 27th. The company reported ($1.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.95) by ($0.35). Crispr Therapeutics had a net margin of 6.77% and a return on equity of 2.35%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $19.77 million. During the same quarter in the previous year, the firm earned ($1.01) EPS. The firm’s revenue was down 86.2% on a year-over-year basis.
Several brokerages have issued reports on CRSP. Citigroup reiterated a “sell” rating on shares of Crispr Therapeutics in a report on Wednesday, August 5th. Canaccord Genuity lifted their price target on shares of Crispr Therapeutics from $80.00 to $84.00 and gave the company a “buy” rating in a research report on Monday, June 15th. SunTrust Banks began coverage on shares of Crispr Therapeutics in a report on Tuesday, July 14th. They set a “buy” rating and a $140.00 price objective on the stock. Roth Capital lifted their price objective on shares of Crispr Therapeutics from $100.00 to $105.00 and gave the company a “buy” rating in a report on Friday, June 19th. Finally, Wells Fargo & Co upped their target price on shares of Crispr Therapeutics from $95.00 to $110.00 and gave the stock an “overweight” rating in a report on Tuesday, July 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the stock. Crispr Therapeutics currently has an average rating of “Buy” and a consensus target price of $90.93.
In related news, CFO Michael John Tomsicek sold 12,000 shares of Crispr Therapeutics stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $92.26, for a total value of $1,107,120.00. Following the sale, the chief financial officer now owns 12,410 shares of the company’s stock, valued at approximately $1,144,946.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Lawrence Otto Klein sold 65,088 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $75.93, for a total value of $4,942,131.84. Following the completion of the transaction, the chief operating officer now owns 58,666 shares in the company, valued at approximately $4,454,509.38. The disclosure for this sale can be found here. Insiders have sold 284,246 shares of company stock valued at $23,578,888 in the last 90 days. 21.40% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Nikko Asset Management Americas Inc. increased its holdings in Crispr Therapeutics by 23.5% in the 1st quarter. Nikko Asset Management Americas Inc. now owns 3,766,541 shares of the company’s stock worth $159,739,000 after acquiring an additional 716,988 shares during the last quarter. FMR LLC increased its stake in shares of Crispr Therapeutics by 18.8% in the second quarter. FMR LLC now owns 1,041,810 shares of the company’s stock worth $76,563,000 after purchasing an additional 164,796 shares in the last quarter. Morgan Stanley increased its stake in shares of Crispr Therapeutics by 233.6% in the first quarter. Morgan Stanley now owns 851,519 shares of the company’s stock worth $36,113,000 after purchasing an additional 596,255 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Crispr Therapeutics by 1.4% in the first quarter. Wellington Management Group LLP now owns 708,952 shares of the company’s stock valued at $30,066,000 after purchasing an additional 9,616 shares during the period. Finally, Orbimed Advisors LLC lifted its stake in shares of Crispr Therapeutics by 26.5% during the 2nd quarter. Orbimed Advisors LLC now owns 697,524 shares of the company’s stock valued at $51,261,000 after buying an additional 146,324 shares in the last quarter. 55.29% of the stock is currently owned by hedge funds and other institutional investors.
Shares of CRSP traded down $3.67 during trading hours on Tuesday, hitting $82.02. The stock had a trading volume of 1,570,215 shares, compared to its average volume of 874,703. Crispr Therapeutics has a 1-year low of $32.30 and a 1-year high of $105.12. The firm has a market capitalization of $5.76 billion, a P/E ratio of 178.30 and a beta of 2.29. The firm has a 50 day simple moving average of $90.72 and a 200-day simple moving average of $65.65.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is the CBOE Russell 2000® Volatility Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.